TY - JOUR
T1 - An ancient viral epidemic involving host coronavirus interacting genes more than 20,000 years ago in East Asia
AU - Souilmi, Yassine
AU - Lauterbur, M. Elise
AU - Tobler, Ray
AU - Huber, Christian D.
AU - Johar, Angad S.
AU - Moradi, Shayli Varasteh
AU - Johnston, Wayne A.
AU - Krogan, Nevan J.
AU - Alexandrov, Kirill
AU - Enard, David
N1 - Funding Information:
We wish to thank Leo Speidel and Aaron Stern for their valuable help using Relate and CLUES, respectively. K.A. is supported by Perkin Elmer Australia and by RISE. Y.S. is supported by the Australian Research Council (ARC DP190103705). R.T. is an ARC DECRA fellow (DE190101069). N.J.K. is funded by grants from the NIH (P50AI150476, U19AI135990, U19AI135972, R01AI143292, R01AI120694, P01AI063302, and R01AI122747); by the Excellence in Research Award (ERA) from the Laboratory for Genomics Research (LGR), a collaboration between UCSF, UCB, and GSK (no. 133122P); by a Fast Grant for COVID-19 from the Emergent Ventures program at the Mercatus Center of George Mason University; by the Roddenberry Foundation; and by funding from F. Hoffmann-La Roche and Vir Biotechnology and gifts from QCRG philanthropic donors. For this work, N.J.K. was supported by the Defense Advanced Research Projects Agency (DARPA) under cooperative agreement no. HR0011-19-2-0020. The authors acknowledge the support of Stanford RISE COVID-19 Crisis Response Faculty Seed Grant Program to Dmitri Petrov. The views, opinions, and/or findings contained in this material are those of the authors and should not be interpreted as representing the official views or policies of the Department of Defense or the U.S. Government. Conceived and designed the experiments, Y.S. R.T. K.A. and D.E.; performed the experiments, Y.S. M.E.L. R.T. S.V.M. W.A.J. and D.E.; interpreted the results, Y.S. M.E.L. R.T. C.D.H. A.S.J. S.V.M. W.A.J. K.A. and D.E.; wrote the manuscript, Y.S. R.T. S.V.M. and D.E.; contributed resources/reagents, N.J.K. K.A. and D.E. The Krogan Laboratory has received research support from Vir Biotechnology and F. Hoffmann-La Roche. N.J.K. has consulting agreements with the Icahn School of Medicine at Mount Sinai, New York, Maze Therapeutics, and Interline Therapeutics; is a shareholder of Tenaya Therapeutics; and has received stocks from Maze Therapeutics and Interline Therapeutics. The other authors declare no competing interests.
Funding Information:
We wish to thank Leo Speidel and Aaron Stern for their valuable help using Relate and CLUES, respectively. K.A. is supported by Perkin Elmer Australia and by RISE . Y.S. is supported by the Australian Research Council ( ARC DP190103705 ). R.T. is an ARC DECRA fellow ( DE190101069 ). N.J.K. is funded by grants from the NIH ( P50AI150476 , U19AI135990 , U19AI135972 , R01AI143292 , R01AI120694 , P01AI063302 , and R01AI122747 ); by the Excellence in Research Award (ERA) from the Laboratory for Genomics Research (LGR), a collaboration between UCSF , UCB , and GSK (no. 133122P ); by a Fast Grant for COVID-19 from the Emergent Ventures program at the Mercatus Center of George Mason University ; by the Roddenberry Foundation ; and by funding from F. Hoffmann-La Roche and Vir Biotechnology and gifts from QCRG philanthropic donors. For this work, N.J.K. was supported by the Defense Advanced Research Projects Agency (DARPA) under cooperative agreement no. HR0011-19-2-0020 . The authors acknowledge the support of Stanford RISE COVID-19 Crisis Response Faculty Seed Grant Program to Dmitri Petrov. The views, opinions, and/or findings contained in this material are those of the authors and should not be interpreted as representing the official views or policies of the Department of Defense or the U.S. Government.
Publisher Copyright:
© 2021 The Authors
PY - 2021/8/23
Y1 - 2021/8/23
N2 - The current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has emphasized the vulnerability of human populations to novel viral pressures, despite the vast array of epidemiological and biomedical tools now available. Notably, modern human genomes contain evolutionary information tracing back tens of thousands of years, which may help identify the viruses that have impacted our ancestors—pointing to which viruses have future pandemic potential. Here, we apply evolutionary analyses to human genomic datasets to recover selection events involving tens of human genes that interact with coronaviruses, including SARS-CoV-2, that likely started more than 20,000 years ago. These adaptive events were limited to the population ancestral to East Asian populations. Multiple lines of functional evidence support an ancient viral selective pressure, and East Asia is the geographical origin of several modern coronavirus epidemics. An arms race with an ancient coronavirus, or with a different virus that happened to use similar interactions as coronaviruses with human hosts, may thus have taken place in ancestral East Asian populations. By learning more about our ancient viral foes, our study highlights the promise of evolutionary information to better predict the pandemics of the future. Importantly, adaptation to ancient viral epidemics in specific human populations does not necessarily imply any difference in genetic susceptibility between different human populations, and the current evidence points toward an overwhelming impact of socioeconomic factors in the case of coronavirus disease 2019 (COVID-19).
AB - The current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has emphasized the vulnerability of human populations to novel viral pressures, despite the vast array of epidemiological and biomedical tools now available. Notably, modern human genomes contain evolutionary information tracing back tens of thousands of years, which may help identify the viruses that have impacted our ancestors—pointing to which viruses have future pandemic potential. Here, we apply evolutionary analyses to human genomic datasets to recover selection events involving tens of human genes that interact with coronaviruses, including SARS-CoV-2, that likely started more than 20,000 years ago. These adaptive events were limited to the population ancestral to East Asian populations. Multiple lines of functional evidence support an ancient viral selective pressure, and East Asia is the geographical origin of several modern coronavirus epidemics. An arms race with an ancient coronavirus, or with a different virus that happened to use similar interactions as coronaviruses with human hosts, may thus have taken place in ancestral East Asian populations. By learning more about our ancient viral foes, our study highlights the promise of evolutionary information to better predict the pandemics of the future. Importantly, adaptation to ancient viral epidemics in specific human populations does not necessarily imply any difference in genetic susceptibility between different human populations, and the current evidence points toward an overwhelming impact of socioeconomic factors in the case of coronavirus disease 2019 (COVID-19).
UR - http://www.scopus.com/inward/record.url?scp=85112667123&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85112667123&partnerID=8YFLogxK
U2 - 10.1016/j.cub.2021.05.067
DO - 10.1016/j.cub.2021.05.067
M3 - Article
C2 - 34171302
AN - SCOPUS:85112667123
VL - 31
SP - 3504-3514.e9
JO - Current Biology
JF - Current Biology
SN - 0960-9822
IS - 16
ER -